Ascentage Pharma announced that it has released updated data of its novel drug candidate AGP-2449, a FAK/ALK/ROS1 tyrosine kinase inhibitor (TKI), in patients with non-small-cell lung cancer (NSCLC) in a poster presentation at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL. This is the third consecutive year in which clinical data from this study of APG-2449 were selected for presentations at the ASCO Annual Meeting. Highlights of these data presented at ASCO 2024 are as follows: Updated study results of novel FAK/ALK/R OS1 inhibitor APG-2449 in patients (pts) with non-small-cell Lung cancer (NSCLC) resistant to second-generation ALK inhibitors.

Patient enrollment and methods: This study comprises dose-escalation and dose-expansion portions. APG-2449 is an investigational drug that has not been approved in any country and region. The four clinical studies of Ascentage Pharma's three drug candidates, including lisaftoclax, presented at this year's ASCO Annual Meeting.

Olverembatinib Updated efficacy results of #11502 Oral (HQP1351) olverembatinib (HQP1351) in patients Report with tyrosinekinase inhibitor (TKI)- resistant succinate dehydrogenas e (SDH)-deficient gastrointestinal stromal tumor (GIST) and paraganglioma Lisaftoclax Safety and efficacy of lisaftoclax, a #6541 Poster (APG-2575) novel BCL-2 inhibitor, in combination Presentation with azacitidine in patients with treatment-naive or relapsed or refractory acute myeloid leukemia. Updated efficacy and safety results of #7078 Poster BCL-2 inhibitorlisaftoclax (APG- 2575) Presentation alone or combined with ibrutiniborrituximab in patients (pts)with Waldens trommacroglobulinemia (WM)APG-2449 Updated study results of novel #3124 PosterFAK/ALK/ROS 1 inhibitor APG-24 49 in Presentation patients (pts) with Non-small-cell lung cancer ("NSCLC") resistant to second-generation ALk inhibitors.